Brian Abrahams

Previewing first-quarter results of biotech companies, Jefferies said it sees some modest misses across the board, going by its deduction that the first quarter tends to be soft and its Rx analysis. However, the firm said this perspective would not dampen its enthusiasm, given a recent string of...

The total number of M&A deals dipped a bit in 2016, but total deal value surged 44 percent to $218.9 billion. With interest rates still historically low and the U.S. economy still firing on all cylinders, 2017 will likely be another strong year for M&A deals. One sector that may be...

Jefferies maintained its Buy rating on Gilead Sciences, Inc. (NASDAQ: GILD) saying that Wall Street underappreciated the impressiveness of last week's phase II 4997 data and shares don't reflect HIV stability and potential pipeline upside. GS-4997 is being studied in nonalcoholic...

Jefferies’ Brian Abrahams believes the share price for Gilead Sciences, Inc. (NASDAQ: GILD) already prices in potential declines for the HCV franchise, which could “enable a setup for upside into continued HIV commercial/clinical success, any strategic moves, or any pipeline surprises...

Jefferies has upgraded Karyopharm Therapeutics Inc (NASDAQ: KPTI) to Buy from Hold as it expects the upcoming STORM data to support Selinexor's potential in refractory multiple myeloma (MM), potentially driving near-term share upside. The brokerage still sees potential for meaningful revenues,...

With the uncertain and declining HCV revenue stream pressuring Gilead Sciences, Inc. (NASDAQ: GILD)'s stock valuation, Jefferies’ Brian Abrahams believes spinning off the HCV assets could unlock value for the company. Abrahams maintains a Hold rating on the company, with a price target of $93...

Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) fell more than 40 percent and touched a new 52-week low. Jefferies downgraded the stock to Hold from Buy following not-so-impressive clinical data. "We believe accumulating data from MRTX and others at ASCO disclosed this weekend continues...

On Tuesday, Jefferies issued a company note on Gilead Sciences, Inc. (NASDAQ: GILD) after an "R&D Day" showed that potential drug candidates in the hepatitis B market may prove effective. Currently, analysts at Jefferies rate Gilead as a Hold with an $100 price target. Brian Abrahams and...

Jefferies recently initiated coverage on the biotech sector, and analyst Brian Abrahams discusses the firm’s bullish take on the sector in a new report. Biotech has had a solid 2015 so far, but Jefferies sees further upside for a number of biotech names. Large-Cap Fundamentals According...

Geron (NASDAQ: GERN) revealed positive results from Imetelstat data this morning. Geron published that Imetelstat, a drug used to treat myelofibrosis, had an overall response rate of 44 percent. Further, the company wrote, “Among 13 patients with leukocytosis, 10 (77 percent) normalized their...